why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

CME Credits: 1.00

Released: 2022-10-28

Bispecific antibodies (bsAb) targeting novel antigens are a promising class of therapeutics for relapsed refractory multiple myeloma (RRMM)., Although hypogammaglobulinemia is expected due to plasma cell depletion,- little is known regarding the degree of humoral immunodeficiency and infectious complications with bsAb. We report on the kinetics of humoral deficiency among patients with RRMM treated with bsAb, the infectious complications, and response to COVID-19 immunization.


Educational Objective
To identify the key insights or developments described in this article


View Full Course